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PTD4-mediated apoptin protein deliveryPTD4-apoptin protein enters cells and harbors tumor-selective cell death activity. Dacarbazine is the
mainstay of treatment for malignant melanoma. In this study, we investigated the cytotoxic effect of PTD4-
apoptin protein and/or dacarbazine in mouse B16-F1 and human A875 and SK-MEL-5 melanoma cells in
vitro and by means of a mouse B16-F1 melanoma model in vivo. PTD4-apoptin protein inhibits the growth of
B16-F1, A875 and SK-MEL-5 melanoma cells in a dose-dependent manner, but not in normal human cell
lines WI-38 and L-02. PTD4-apoptin combined with dacarbazine revealed a synergistic cytotoxic effect
(coefﬁcient of drug interactionb1) in all three different tumor cell lines. In vivo, PTD4-apoptin protein and
dacarbazine alone effectively inhibited the growth of B16-F1 melanoma in C57BL/6 mice. Strikingly,
combined PTD4-apoptin/dacarbazine treatment signiﬁcantly increased the antitumor effect in comparison to
the single treatments. As important, a combined PTD4-apoptin/dacarbazine treatment with a 50% reduction
of dacarbazine revealed similar antitumor activities, without detectable hematologic side effects. A combined
PTD4-apoptin/dacarbazine treatment represents a promising novel efﬁcient and safe anticancer strategy.hong University of Science and
a. Tel.: +86 2762608280; fax:
vier OA license.© 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Worldwide, the incidence and mortality of cutaneous malignant
melanoma are continuously increasing (Garbe and Leiter, 2009;
MacKie et al., 2009). Localized melanoma has a good prognosis after
adequate surgical therapy, but once hematogenous metastasis occurs,
the prognosis is very poor despite a large number of clinical trials with
various chemotherapeutic agents and biological modiﬁers (Kasper
et al., 2007; Trinh, 2008). The alkylating agent dacarbazine has been
approved for treatment of metastatic melanoma and is considered the
standard by which other therapies are evaluated (Agarwala, 2009).
However, in recent years, randomized trials examining dacarbazine as
a single agent have demonstrated its response rates ranging from 6%
to 12% without clear impact on overall survival (Agarwala, 2009;
Hauschild et al., 2008). To date no alternatives have been reported
(Eggermont and Kirkwood, 2004; Lillehammer et al., 2007). There-
fore, the development of a new treatment approach is needed.
Apoptin is a small protein derived from chicken anemia virus
(CAV), which can selectively induce cell death in tumor cells, but not
in normal cells (Noteborn, 2009; Noteborn et al., 1994; Rohn andNoteborn, 2004; Zhang et al., 2003). In transformed human cells,
apoptin becomes selectively phosphorylated. Apoptin forms multi-
meric complexes, which interact in tumor cells with chromatin
structures. Apoptin synthesis in tumor cells results in enhanced
tumor suppressor ceramide levels, indicating that sphingolipids play
a crucial role in apoptin's tumor-selective cell death. Apoptin induces
G2/M cell cycle arrest by interaction with the anaphase promoting
complex/cyclosome resulting in p73/PUMA-induced cell death.
Apoptin induces cell death independently of the tumor suppressor
p53 and can be stimulated by Bcl-2 (Backendorf et al., 2008;
Noteborn, 2009; Grimm and Noteborn, 2010). All these features are
indicative that apoptin can exert its activity under conditions where
most currently used anticancer agents fail (Maddika et al., 2006;
Noteborn, 2005).
Based on the above properties, apoptin is expected to be a
potential anticancer therapy candidate. It is reported that the
expression of apoptin alone or in combination with other (chemo)
therapeutics can inhibit tumor cell growth in vitro or inmouse bearing
tumor models (Lian et al., 2007; Olijslagers et al., 2007; Peng et al.,
2007; Van der Eb et al., 2002). To avoid the potential limitations
related to exogenous gene transduction (Bagi, 2005; Liu, 2006) and to
expand apoptin's antitumor therapy potential, our laboratory devel-
oped a novel apoptin protein therapy. The protein transduction
domain 4 (PTD4) was fused to the apoptin protein facilitating the
apoptin protein to be delivered across cellular membranes in a very
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signiﬁcantly inhibited tumor growth in vivo without cytotoxic side
effects on normal tissue as shown for HepG2, HeLa and SGC7901
tumor xenografted nude mouse models (Sun et al., 2009).
In the present study, we examined whether PTD4-apoptin can
enhance the antitumor potential of dacarbazine. Therefore, we
investigated the effects of PTD4-apoptin protein alone or in
combination with dacarbazine in vitro and examined their anticancer
efﬁcacy and hematologic side effects in vivo. PTD4-apoptin and
dacarbazine reveal a synergistic antitumor effect with reduced side
effects.
2. Material and methods
2.1. Anticancer drugs
Dacarbazine was purchased from Sigma-Aldrich, Inc. (St. Louis,
MO, USA) and was activated by exposure to light for 1 h before it was
used in vitro. Next, dacarbazinewas dissolved in 1 M hydrochloric acid
according to the supplier's instructions and diluted to various
concentrations with culture medium. When dacarbazine was inter-
peritoneally injected in tumor-bearing or tumor-free mice, it was
dissolved in 0.9% NaCl solution to a speciﬁc concentration. PTD4-
apoptin protein and PTD4-EGFP protein were prepared according to
the methods described by Sun et al. (2009). Before the start of the in-
vitro experiments, the lyophilized powders of PTD4-apoptin proteins
and PTD4-EGFP proteins were dissolved in sterile phosphate-buffered
saline (PBS). For in-vivo experiments, PTD4-apoptin protein and
PTD4-EGFP protein was dissolved in PBS+30% glycerol solution and
applied carefully on the tumor-bearing epidermis.
2.2. Cell culture
The mouse melanoma cell line B16-F1, the human melanoma cell
line A875, normal human embryonic lung ﬁbroblast WI-38 cell line,
and human normal hepatocyte L-02 cell line were purchased from the
China Center for Type Culture Collection (Wuhan, PR China). The
human melanoma cell line SK-MEL-5 was kindly provided by
professor Xiongwen Wu, Department of Immunology, Tongji Medical
College, Huanzhong University of Science and Technology, Wuhan, PR
China. B16-F1, A875 and SK-MEL-5 cells were all cultured in DMEM
medium supplemented with 10% fetal bovine serum (HyClone, Logan,
UT, USA), 100 units/ml penicillin, and 100 μg/ml streptomycin in a
humidiﬁed atmosphere of 5% CO2 at 37 °C. WI-38 and L-02 cells were
cultured in RPMI 1640 (Gibco) supplemented with 10% fetal bovine
serum in a humidiﬁed atmosphere of 5% CO2 at 37 °C. WI-38 cells
were used between passages 6 and 12.
2.3. Cell viability assay and combined effect evaluation
B16-F1 cells, A875 cells or SK-MEL-5 cells or L-02 cells were
plated in 96-well plates at a density of 3×103 cells per well,
respectively. WI-38 cells were plated in 96-well plates at a density
of 2.5×103 cells per well. After 24 h, PTD4-apoptin protein and/or
dacarbazine was added into wells with an indicated concentration.
PTD4-EGFP, as the negative control of PTD4-apoptin protein, was also
added into wells in the same way. After incubation for 48 h, 20 μl of
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)
solution (5 mg/ml in PBS, Sigma, St. Louis, MO, USA) was added into
each well. After incubation at 37 °C for 4 h, the mediumwas discarded
completely, and 150 μl dimethyl sulfoxide was added into eachwell to
dissolve the formazan crystals of the cell. Next, its absorbance was
measured by a microplate reader (Tecan Sunrise, Mannedorf,
Switzerland) at 570 nm as detection wavelength and 630 nm as
reference wavelength. Each experiment was performed with ﬁve
parallel observations and repeated three times in an independentway.The survival ratio (%) was calculated using the following equation:
survival ratio (%)=(average absorbance of treated group/average
absorbance of control group)×100. IC50 was deﬁned as the drug
concentration at which 50% of the cell growth was inhibited and was
analyzed by means of SigmaPlot 8.0.
The coefﬁcient of drug interaction (CDI) was used to analyze the
nature of the drug interaction between PTD4-apoptin protein and
dacarbazine (Cao and Zhen, 1989; Xu et al., 2007). CDI was calculated
as follows: CDI=AB/(A×B). According to the absorbance of each
group, AB is the ratio of the 2-drug combination group to the control
group in OD570/630, and A or B is the ratio of the single drug group to
the control group in OD570/630. CDIb1 indicates synergism, CDIb0.7
indicates a signiﬁcantly synergistic effect, CDI=1 indicates additivity
and CDIN1 indicates antagonism.
2.4. DAPI staining
B16-F1 cells were seeded in 6-well plates containing cover slips at
a concentration of 1.5×105 cells per well. After culturing for 24 h,
15 μg/ml PTD4-apoptin or 250 μM dacarbazine alone or a 2-drug
combination was added into the wells. The cells were incubated
during 48 h. Next, the morphology of cells was monitored under an
inverted light microscope. Then the cover slips were washed twice
with PBS, ﬁxed with 4% paraformaldehyde for 20 min, washed with
PBS and ﬁnally incubated with 1 μg/ml DAPI (4′,6′-diamidino-2-
phenylindole, Roche Applied Science, Indianapolis, IN, USA) for
15 min. After washing with PBS, cells were analyzed by means of
ﬂuorescent microscopy (Olympus, Tokyo, Japan) with a peak
excitation wave length of 340 nm. The characteristics of nuclear
morphological changes of cell death such as the condensation of
nuclear chromatin and fragmentation were examined.
2.5. Annexin-V/propidium-iodide (PI) double staining assay
B16-F1 cells were seeded in 6-well plates at a concentration of
1.5×105 cells per well and incubated with 15 μg/ml PTD4-apoptin or
250 μM dacarbazine alone or a 2-drug combination. After 48 h, cells
were collected, washed with PBS for 2 times and suspended with
binding buffer containing 2 μl FITC-labeled Annexin-V and 5 μl PI
according to the instructions of the supplier's kit (Kaigi, Nanjing,
China). After at least 15 min of incubation, the cells were examined by
ﬂow cytometric analysis (BD LSR II Flow Cytometer; BD Biosciences,
San Jose, CA, USA). Cells in early stages of apoptosis were Annexin-V
positive; whereas, cells that were both Annexin-V and PI positive
were regarded to be in a late stage of apoptosis.
2.6. In-vivo melanoma tumor model and treatments
Female C57BL/6 mice (7–8 weeks old) were obtained from the
Experimental Animal Center of the Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China. All animal
studies were carried out in accordance with the “Guide for the Care
and Use of Laboratory Animals” and approved by the Institute of
Laboratory Animal of Hubei Province. To establish the tumor model,
2×106 B16-F1 cells were suspended in 100 μl PBS buffer and injected
subcutaneously into the right hind groin of each mouse.
Firstly, the inhibitory effect of PTD4-apoptin on the B16-F1
melanoma growth in comparison to PTD4-EGFP protein and PBS
was examined. We established 12 tumor-bearing mice, and after the
tumors were clearly visible, the mice were divided randomly into
three groups. During a treatment period of 9 days, every day the
tumor-bearing epidermis was applied with 100 μg PTD4-apoptin,
PTD4-EGFP or PBS.
Subsequently, we detected the inhibitory effect of the combination
of PTD4-apoptin and dacarbazine. The tumors were established as
described above. After the tumors were clearly visible, 35 tumor-
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group):① PTD4-apoptin protein treatment group (100 μg/tumor/day,
every day) ② dacarbazine treatment group (70 mg/kg, once every
2 days, ﬁve times) ③ “full dose” drug combination group (dacarba-
zine, 70 mg/kg, once every 2 days, ﬁve times+PTD4-apoptin protein,
100 μg/tumor/day, every day)④ “half dose” drug combination group
(dacarbazine, 35 mg/kg, once every 2 days, ﬁve times+PTD4-apoptin
protein, 100 μg/tumor/day, every day) and ⑤ control group (PBS, on
the tumor-bearing epidermis, every day). PTD4-apoptin or PBS
preparations were carefully applied on the tumor-bearing epidermis,
whereas dacarbazine was intraperitoneally injected in tumor-bearing
mice. The control, single and combined treatments lasted for 15 days.
2.7. Analysis of an in-vivo antitumor effect
The antitumor effect of PTD4-apoptin protein and/or dacarbazine
treatment was determined as follows. The length and width of the
tumors were measured using calipers before the experiment and
measured every 2 days till the end of the experiments. The tumor
volume was calculated according to the following formula: volu-
me=length×width2×0.52. When the experiment was terminated,
the mice were killed by cervical dislocation.
The treated mice, within the experiment examining the inhibitory
effect of PTD4-apoptin protein in comparison to PTD4-EGFP and PBS,
were sacriﬁced after 9 days. The tumor tissue from each mouse was
excised, photographed and weighed.
After a 15-day treatment, the mice within the in-vivo combinato-
rial experiments were all sacriﬁced. Two mice from each group were
randomly chosen and a part of their tumor tissue covered by
epidermal tissue was excised and ﬁxed for immunohistochemistry
to detect the possible presence of PTD4-apoptin protein. The tumors
from the other 5mice were excised, photographed, weighed and ﬁxed
for Tdt-mediated dUTP nick-end labeling (TUNEL) assays. The growth
inhibition rate was calculated according to the formula: the inhibition
rate=(mean tumor weight of control group−mean tumor weight of
treatment group)/(mean tumor weight of control group)×100%.
2.8. Immunohistochemistry and TUNEL staining
The excised tumors or tumors covered with epidermal tissue were
ﬁxed with 4% paraformaldehyde, and parafﬁn-embedded sections
were prepared for carrying out hematoxylin and eosin (HE) staining,
TUNEL assays or immunohistochemistry. HE staining was performed
by routine methods. TUNEL staining was performed using the in-situ
apoptosis detection kit POD, according to the supplier's protocol
(Roche Applied Science, Mannheim, Germany). Immunohistochemi-
cal staining for His-tagged PTD4-apoptin by anti-His antibodies (GE
Healthcare, Piscataway, NJ, USA) was performed according to the
routinemethod to show the presence of PTD4-apoptin protein. TUNEL
staining and immunohistochemistry were both colored by means of
AEC (3-amino-9-ethylcarbozole).
2.9. Assay for evaluating hematologic side effects
The experiments for determining possible side effects by PTD4-
apoptin and/or dacarbazine were carried out in tumor-free animals.
25 female C57BL/6 mice were divided randomly into ﬁve groups (5
mice in each group). The treatment regimen was the same as
described for the tumor-bearing mice models. Fifteen days after
treatment, peripheral blood cells were collected from mice by cardiac
puncture into K2EDTA-containing tubes and analyzed by Automatic
Blood Chemistry Analyzer (sysmex, xs-800i, Japan). The following
blood parameters were measured and compared with normal values:
red and white blood cell and platelet count and determination of the
hemoglobin level. A decrease in hemoglobin, platelets and whiteblood cells in comparison to normal value indicates bone marrow
suppression.
2.10. Statistics
The statistical signiﬁcance of differences was evaluated by the
t-test using SPSS software (version 13.0). A P value of less than
0.05 (*) or less than 0.01 (**) was considered to be signiﬁcant.
Data presented in the ﬁgures represent the mean±standard error.
3. Results
3.1. Anti-proliferation effect of PTD4-apoptin protein and/or dacarbazine
on mouse and human melanoma cells in vitro
Under in-vitro conditions, we have examined the cytotoxic effects
of PTD4-apoptin and dacarbazine alone or combined with each other
on B16-F1, A875, and SK-MEL-5 tumor cells. The effects of PTD4-
apoptin or dacarbazine on normal human WI-38 and L-02 cells and
the cytotoxicity of PTD4-EGFP protein onmelanoma B16-F1 and A875
cells or normal WI-38 and L-02 cells were examined. Firstly, the
inhibitory effect of increasing concentrations of PTD4-apoptin, PTD4-
EGFP protein (5, 10, 15, 20, and 25 μg/ml) or dacarbazine (62.5, 125,
250, 500, 1000, and 2000 μM) on the cell viability of B16-F1, A875,
SK-MEL-5, WI-38 and L-02 cells was determined by means of MTT
assay. The results indicated that both PTD4-apoptin and dacarbazine
inhibit cell growth in a dose-dependent manner (Fig. 1A, C). The IC50
of PTD4-apoptin protein in B16-F1 cells, A875 cells and SK-MEL-5
cells was 19.3±4.3 μg/ml, 17.5±5.1 μg/ml and 14.9±4.4 μg/ml,
respectively. The IC50 of dacarbazine in the same cells was
259.5±22.7 μM, 287±20.9 μM and 380±29.8 μM, respectively.
Although less sensitive than tumor cells, normal human WI-38 and
L-02 cells also showed signs of growth inhibition upon dacarba-
zine treatment (1 C), but normal cells treated with PTD4-apoptin
protein did not show any signiﬁcant signs of growth inhibition
(Fig. 1A). The IC50 of dacarbazine in normal cells WI-38 and L-02
was 526.46±37.53 μM and 366.94±28.72 μM, respectively. B16-F1
and A875 tumor cells and WI-38 and L-02 normal cells treated with
PTD4-EGFP protein did not show any signiﬁcant signs of growth
inhibition (Fig. 1B). The results indicate that PTD4-apoptin protein
can selectively act on tumor cells, whereas chemotherapy agent
dacarbazine has a rather limited selectivity.
Three doses of PTD4-apoptin protein (5, 10 and 15 μg/ml) were
used in combination with different concentrations of dacarbazine
(62.5, 125, 250, 500, and 1000 μM) mixed at a ﬁxed ratio (1:1, v/v),
respectively. The obtained MTT-results showed that PTD4-apoptin
protein signiﬁcantly increased the cytotoxicity of dacarbazine in
mouse melanoma B16-F1 cells (Fig. 2A). For example, in the presence
of 5, 10 and 15 μg/ml PTD4-apoptin, the IC50 of dacarbazine in B16-F1
cells reduced from259.5±22.7 μMto 127.1±18.5 μM, 86.4±13.9 μM
and 43.5±8.8 μM, respectively (Fig. 2A).
To analyze whether the synergistic inhibitory effect of combined
PTD4-apoptin protein and dacarbazine also holds true for human
melanoma cells, the human melanoma cell lines A875 and SK-MEL-5
were treated with PTD4-apoptin and dacarbazine. The obtained MTT-
results indicate that also in the two human tumor cell lines PTD4-
apoptin protein signiﬁcantly increased the cytotoxicity of dacarbazine
(Fig. 2B, C). In the presence of 5, 10 and 15 μg/ml PTD4-apoptin
protein, the IC50 of dacarbazine in A875 cells was reduced from
287±20.9 μM to 124±17.3 μM, 83.6±10.7 μM and 40.3±7.9 μM,
respectively. The IC50 of dacarbazine in SK-MEL-5 cells was
reduced from 380±29.8 μM to 241±12.3 μM, 101.6±8.6 μM and
34.3±5.7 μM.
Finally, the coefﬁcient of drug interaction (CDI) was determined to
evaluate the nature of the drug interaction. The results showed that in
all analyzed cases the CDI was b1, which means a synergistic
Fig. 1. The dose–effect curve of PTD4-apoptin protein, PTD4-EGFP protein or
dacarbazine (DTIC) on the cell viability in melanoma cells B16-F1, A875 and SK-MEL-5
or normal human cells WI-38 and L-02. The cell lines were incubated with (A) various
concentrations of PTD4-apoptin protein, with (B) various concentrations of PTD4-
EGFP protein, with (C) various concentrations of DTIC during 48 h, respectively. The
cell viability was determined using MTT assay. Data are presented as mean±S.D.
(error bar) of three independent experiments.
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the three cell lines. Under some conditions for B16-F1 cells (Fig. 2A’),
the CDI was even b0.7. For example, for the combination of 10 μg/ml
PTD4-apoptin and500 μMdacarbazine, or the combination of 15 μg/ml
PTD4-apoptin and 250 μM, 500 μM, or 1000 μM dacarbazine, the CDI
was always b0.7, which showed a signiﬁcant synergistic inhibitory
effect between PTD4-apoptin protein and dacarbazine. A CDIb0.7
was also found for certain ratios of PTD4-apoptin and dacarbazine in
A875 cells and SK-MEL-5 cells (Fig. 2B’, C’).
3.2. Effects of PTD4-apoptin protein and/or dacarbazine on B16-F1
cell morphology
Next, we examined the morphological effects in B16-F1 cells
triggered by the various treatment strategies. Firstly, the cells were
incubated for 48 h with 15 μg/ml PTD4-apoptin protein, 250 μMdacarbazine, a combination, or untreated. As shown in Fig. 3A (a–d),
the untreated B16-F1 cells grew well and the cytoskeletons were
clearly detectable. Cells treated with dacarbazine were equivocal, and
a few cells were swollen or broken. After treatment with PTD4-
apoptin, some cells were swollen and even broken. A large proportion
of cells treated with the 2-drug combination underwent either
swelling or were broken.
In addition, we examined the changes in the nuclear morphology
by staining with DAPI. As shown in Fig. 3A (e–h), untreated B16-F1
cells demonstrated homogeneously distributed chromatin within
their nuclei, while treated cells presented the morphological features
of apoptotic cells in different degrees, such as chromatin condensa-
tion and nuclear fragmentation. Most of the cells treated with the
dacarbazine/PTD4-apoptin revealed abundant cell death features.
Cells treated with PTD4-apoptin show a mediate amount of dead
cells, whereas relatively few killed cells were observed in cells
treated with dacarbazine. We conclude that a combined PTD4-
apoptin/dacarbazine treatment is more potent in inducing cell death
in comparison to the single treatments.
3.3. Increased apoptosis rate induced by a combination of PTD4-apoptin
protein and dacarbazine in B16-F1 cells
To further specify the increased cell death rate induced by PTD4-
apoptin/dacarbazine, treated cells were analyzed by means of an
Annexin-V/PI staining assay. Compared with the mock-treated
control group, the proportion of apoptotic cells increased upon 48 h
exposure to 250 μM dacarbazine, 15 μg/ml PTD4-apoptin protein or a
combination with the total apoptosis rate of 13%±1.7%, 21.8%±1.6%,
and 59.5%±5%, respectively (Fig. 3C). Fig. 3B shows that the
proportion of both early and late apoptotic cells is the highest for
the combination treatment, whereas dacarbazine revealed the
slightest early/late apoptosis induction.
The morphological analysis and the Annexin-V/PI staining assay
indicated that PTD4-apoptin protein combined with dacarbazine
achieved the most prominent apoptotic-inducing effect in B16-F1
melanoma-derived tumor cells.
3.4. In vivo, PTD4-apoptin/dacarbazine combinatorial treatment results
in enhanced anticancer activities
Toexamine the anticancer effects of a combination strategy based on
PTD4-apoptin and dacarbazine under in-vivo conditions, 12 C57BL/6
mice bearing subcutaneous melanoma tumors were randomly divided
into 3 groups and treated with PBS, PTD4-EGFP or PTD4-apoptin
protein as described in the Materials and methods section. After 9 days
of treatment, the tumors were excised and weighed. The results
showed that the tumor weights of PTD4-apoptin-treated mice were
about one third of the tumor weights of control mice treated with PBS
or PTD4-EGFP (Pb0.01). The tumor weights of the PBS and PTD4-EGFP
control groups had no signiﬁcant difference (P=0.852) in comparison
to each other (Fig. 4A). The excised tumors of each treated group are
shown in Fig. 4B.
The results indicate that PTD4-apoptin inhibits the growth of the
subcutaneous melanomas effectively whereas PTD4-EGFP did not.
Therefore, one can conclude that the observed tumor growth inhibition
is speciﬁcally due to PTD4-apoptin protein and not just due to an
immunogenic effect against the transduced recombinant protein.
Next, we examined whether the synergistic cytotoxic effect of
PTD4-apoptin and dacarbazine observed in vitro could be reproduced
under in-vivo conditions. To that end, 35 female C57BL/6 bearing
subcutaneous melanoma tumors were randomly divided into 5
groups and treated with PTD4-apoptin protein and/or dacarbazine.
During 15 days of treatment, the size of the tumors was analyzed
every 2 days. As shown in Fig. 4C, the tumor growth was signiﬁcantly
inhibited in all treatment groups (Pb0.05). The tumor growth of
Fig. 2. The inhibitory effects of PTD4-apoptin protein combined with dacarbazine (DTIC) on cell viability of mouse and human melanoma cells and the coefﬁcient of drug interaction
(CDI). Panel A shows the data for B16-F1 cells, B for A875 cells and C for SK-MEL-5 cells. The various cells were incubated with 5, 10, and 15 μg/ml PTD4-apoptin protein combined
with 62.5, 125, 500 or 1000 μMDTIC during 48 h. The cell viability was determined usingMTT assay. Data are presented asmean±S.D. (error bar) of three independent experiments.
**Pb0.01 and *Pb0.05 compared with DTIC treatment. (A’, B’, C’) The CDI of PTD4-apoptin protein combined with DTIC on (A’) B16-F1 cells, (B’) A875 cells and (C’) SK-MEL-5 cells.
CDIb1 means synergistic inhibitory effect between PTD4-apoptin protein and dacarbazine, whereas CDIb0.7 indicates a signiﬁcantly synergistic inhibitory effect.
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that of the dacarbazine group (Pb0.05). The tumor growth of the two
2-drug combination groups was signiﬁcantly lower than that in each
single treatment groups (Pb0.05). The growth of the tumors treated
with PTD4-apoptin and a 50% reduced dacarbazine was not
signiﬁcantly different in comparison to tumors treated with PTD4-
apoptin and high dose dacarbazine (P=0.237).
Fifteen days after treatment, the mice were killed and the tumors
were excised. Macroscopic analysis also showed that the size of
tumors treated with PTD4-apoptin and reduced dacarbazine or high
dose dacarbazine was signiﬁcantly smaller than those treated with a
single drug or of the control group (Fig. 4D). In addition, we
determined the tumor growth inhibition rate by weighing the excised
tumor according to the formula described in the Materials and
methods section. The tumor growth inhibition rate in the dacarbazine
and PTD4-apoptin treatment groups was 59.1% and 70.4%, respective-ly. The tumor growth inhibition rate of the PTD4-apoptin and “50% or
100%” dacarbazine treatment groupwas 90.2% and 93.2%, respectively.
3.5. PTD4-apoptin protein penetrates into tumor cells via
epidermal tissue
To ascertain the contribution of PTD4-apoptin protein to the
observed tumor growth reduction, we determined whether the PTD4-
apoptin protein could be transduced into the melanoma tumor tissue
via epidermal tissue. To that end, we analyzed the presence of PTD4-
apoptin protein in sections derived from each treatment group
consisting of the epidermis covering tumor tissue by immunohisto-
chemistry. HE staining showed the characteristic morphology of both
the epidermal and tumor tissue (Fig. 5A). Antibodies directed against
the histidine tag of PTD4-apoptin, indicated its presence in the
epidermal and tumor tissue. PTD4-apoptin protein was transduced
Fig. 3.Morphological changes and apoptosis in B16-F1 cells treated with 250 μM dacarbazine (DTIC), 15 μg/ml PTD4-apoptin protein, a 2-drug combination or untreated (control)
for 48 h. (A) Phase-contrast micrographs (a, b, c, d. magniﬁcation: ×200) and ﬂuorescence micrographs (e, f, g, h) showed the morphological changes in B16-F1 cells: (a, e) control;
(b, f) 250 μMDTIC; (c, g) 15 μg/ml PTD4-apoptin protein; and (d, h) a 2-drug combination. B16-F1 cells subjected to DAPI staining, which is illustrative for chromatin condensation,
nuclear fragmentation or apoptotic body formation (indicated like three different types of arrow), all indicative for apoptosis. (B) Apoptosis rate determined by Annexin-V/PI
staining. Early apoptotic cells are Annexin-V positive, PI-negative (lower right), whereas late apoptotic cells are Annexin-V- and PI-positive (upper right). (C) The apoptotic rates of
B16-F1 cells treated with PTD4-apoptin protein and/or DTIC for 48 h. The apoptotic rate of the 2-drug combination was signiﬁcantly higher than that of DTIC alone or PTD4-apoptin
alone (**Pb0.01).
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PTD4-apoptin protein alone or in combination with dacarbazine.
Tumor tissues derived fromthenegative control groupanddacarbazine-
only group were, as expected, negative (Fig. 5B).
3.6. In vivo, PTD4-apoptin/dacarbazine treatments are cytotoxic via
induction of apoptosis
To investigate the underlying process of the antitumor effect in
tumor-bearing C57BL/6 mice treated with PTD4-apoptin protein,
dacarbazine or the combination, sections of all tumors were prepared
for detection of the level of cell death by means of TUNEL assay. The
results showed that tumors treated with both PTD4-apoptin/dacar-bazine regimens contained many TUNEL-positive cells. Tumors
treated with PTD4-apoptin protein also contained a relativelymediate
level of dead cells, whereas dacarbazine-treated tumors contained a
few apoptotic cells. Control tumors did reveal almost no TUNEL-
positive cells (Fig. 5C).
Therefore, we conclude that in vivo PTD4-apoptin protein
combined with dacarbazine induces an enhanced inhibition of
melanoma tumor growth via induction of apoptosis.
3.7. Hematologic side effects
Finally, we examined whether the various PTD4-apoptin and/or
dacarbazine treatment regimens cause hematologic side effects in the
Fig. 4. In B16-melanoma bearing mice PTD4-apoptin protein enhances antitumor activity of dacarbazine (DTIC). (A, B) Inhibition of B16-F1 melanoma tumor volume by PTD4-
apoptin protein in comparison to PTD4-EGFP protein or PBS treatment. The tumor mice were treated every day with PTD4-apoptin protein, PTD4-EGFP and PBS during 9 days.
(A) Diagrams showed the mean tumor volumes±standard deviation of the excised tumors after the treatment regimens with PTD4-apoptin, PTD4-EGFP or PBS. (B) Photographs
of the excised tumors of all the treated groups and of the control group. (C) Volumes of the melanoma tumor tissue during treatment with DTIC, PTD4-apoptin protein, “half
dose” drug combination, “full dose” drug combination or control. The tumor size was measured every 2 days. The results are expressed as the mean±S.D. from 7 tumor-bearing
mice in each group. *Pb0.05 compared between a single treatment and combined treatment. (D) (a) Macroscopic appearances in drug-treated mice or control ones. (b) Excised
tumors of all the treated groups and of the control group. Note the signiﬁcant decrease in tumor volume associated with “half dose” and “full dose” drug combination treatment
in comparison to the control and mono-treated ones.
23J. Jin et al. / European Journal of Pharmacology 654 (2011) 17–25treated mice. Tumor-free mice were treated with dacarbazine and/or
PTD4-apoptin as described for the tumor-bearing mice experiments.
Fifteen days after treatment, blood was collected by heart puncture.
As shown in Table 1, upon dacarbazine alone or a combination
treatmentwith high dose dacarbazine and PTD4-apoptin a decrease in
hemoglobin, platelets and white blood cells was observed in
comparison to the control-treated group. PTD4-apoptin protein
alone and the combination treatment based on 50%-reduced
dacarbazine and PTD4-apoptin had no signiﬁcant negative effect on
the hemoglobin level, as well as on the amount of platelets and white
blood cells. The obtained results suggest that high concentrations of
dacarbazine resulted in bone marrow suppression, whereas PTD4-
apoptin alone and “half dose” combinatorial treatment do not.
4. Discussion
Here, we explored new approaches for treating melanoma. Our
data show for the ﬁrst time that a combinatorial treatment of B16-F1
melanoma in vitro and in vivo based on PTD4-apoptin protein and
dacarbazine represents an effective antitumor strategy without
detectable side effects. Dacarbazine used as single-agent therapy is
the approved therapy for patients with metastatic melanoma, but its
response rates are disappointing and the effect is not sustained(Lillehammer et al., 2007). Other single-agent chemotherapies such
as temozolomide, taxanes, cisplatin, carboplatin or immunothera-
peutic agents such as interferons and interleukin-2 achieve similar
results as dacarbazine (Hauschild et al., 2008; Yang and Chapman,
2009). Combination chemotherapy regimens such as dartmouth
regimen (dacarbazine/carmustine/cisplatin/tamoxifen), CVD (cisplatin/
vinblastine/dacarbazine) or biochemotherapy regimens containing
interferon-α, interleukin-2 and 3 different cytotoxic drugs (cisplatin,
vinblastine, and dacarbazine) have no overall survival beneﬁt or are
highly toxic compared to dacarbazine (Trinh, 2008; Yang and
Chapman, 2009).
In vitro, PTD4-apoptin protein alone had a dose-dependent
cytotoxicity on the growth of mouse B16-F1 melanoma cells as well
as on human A875 and SK-MEL-5 melanoma cells. However, PTD4-
apoptin had no detectable negative effect on the analyzed normal
cells. The obtained CDI results showed that PTD4-apoptin protein acts
synergistically with dacarbazine in the analyzed mouse and two
human melanoma cell lines. These results suggest that a combinato-
rial treatment consisting of PTD4-apoptin local treatment and
systemic delivery of dacarbazine can be more beneﬁcial than the
separated single treatments.
Indeed, our in-vivo data conﬁrmed our in-vitro observed synergis-
tic behavior between PTD4-apoptin protein and dacarbazine
Fig. 5. PTD4-apoptin protein penetrates through normal and tumor tissue resulting in apoptosis in tumor tissue only. (A) HE staining showed the characteristic morphology of
both the epidermal and tumor tissue (Tu). (Magniﬁcation: ×100). (B) Immunohistochemistry analysis shows the presence of PTD4-apoptin protein in both epidermal and
melanoma tissues when supplied on the epidermis only or in combination with intraperitoneally injected dacarbazine (DTIC). (Magniﬁcation: ×100). (C) TUNEL analysis reveals
that PTD4-apoptin enhances the apoptotic activity of DTIC. The cells undergoing apoptosis are colored red. (Magniﬁcation: ×400).
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pressed the growth of the subcutaneous melanomas signiﬁcantly
higher than eithermono-therapy. Lowering the dose of dacarbazine to
50% did not result in a signiﬁcant reduction of antitumor activity of the
combinatorial therapy. One can conclude that also under in-vivo
conditions apoptin's tumor-selective cell death characteristics are
enhancing the dacarbazine cell killing activity.
In vivo, TUNEL and Annexin-V/PI staining showed that the
percentage apoptotic cells were signiﬁcantly higher in tumor tissue
treated with the both PTD4-apoptin and dacarbazine versus the singleTable 1
Blood cell and hemoglobin parameters of tumor-free mice after administration of dacarba
described in the Materials and methods section.
Parameter Measured value
Control DTIC PTD4-a
Leucocytes (*109/l) 5.6±0.4 3.3±0.7 6.0±0
Erythrocytes (*1012/l) 9.1±0.3 6.0±1.3 9.8±0
Hemoglobin (g/l) 134.7±3.7 95.5±6 142±5
Platelets (*109/l) 921.7±50 600±83 939±2drug treatment groups. All these results indicate that PTD4-apoptin/
dacarbazine combination treatments inhibit tumor growth more
effectively than single treatments by increasing the apoptosis
induction levels.
In a previous study, Sun et al. (2009) have demonstrated that local
treatment with PTD4-apoptin results in the presence of PTD4-apoptin
in e.g. liver, brain, kidney and lung tissue of nude mice without
resulting in any detectable cytotoxic effect. In this study, we examined
possible hematologic side effects of treatments based on PTD4-
apoptin and/or dacarbazine of tumor-freemice. Dacarbazine harbors azine (DTIC), PTD4-apoptin protein or its combinations. The experimental details are
Normal value
poptin DTIC+PTD4-apoptin
Full dose Half dose
.6 4.4±0.6 5.6±0.3 5.1–11.6
.3 7.3±0.4 9.2±0.5 8.7–10.5
108.3±7.1 129±6.2 120–150
3 865.8±62 908.3±69 100–1000
25J. Jin et al. / European Journal of Pharmacology 654 (2011) 17–25main side effect consisting of bone marrow suppression (Wolf et al.,
2006). PTD4-apoptin alone or a combination treatment of PTD4-
apoptin and 50% reduced dacarbazine had no detectable effect on
bone marrow suppression. A high dose of dacarbazine treatment
alone or combined with PTD4-apoptin revealed severe bone-marrow
suppression.
In conclusion, PTD4-apoptin protein combined with dacarbazine
showed synergistic inhibitory effects on the growth of mouse
melanoma in vitro and in vivo. As important, in-vivo PTD4-apoptin
combined with “half dose” dacarbazine regimen led to synergistic
antitumor effects without side effects on bone marrow suppression.
Our preclinical observations indicate that a combinatorial therapy
based on PTD4-apoptin protein and dacarbazine is a promising
efﬁcient and safe anticancer strategy. The PTD4-apoptin protein
approach can be used for topical applications, which implies that our
method is limited to treatments of cancers such as squamous cell
carcinoma or precancerous skin lesions.
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